CellType - About the company
CellType is a seed company based in New York City (United States), founded in 2025 by Ivan V and David Van Dijk. It operates as an AI-driven platform focused on drug discovery through biological simulation. CellType has raised $500K in funding. The company has 214 active competitors, including 71 funded and 13 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and Valo Health.
Company Details
AI-driven platform focused on drug discovery through biological simulation. The company utilizes artificial intelligence to simulate human biology and develop targeted drug therapies. The company leverages large datasets and machine learning algorithms to understand the patterns governing drug response and toxicity.
- Website
- www.celltype.com/
- Social
- Email ID
- *****@celltype.com
Key Metrics
Founded Year
2025
Location
New York City, United States
Stage
Seed
Total Funding
$500K in 1 round
Latest Funding Round
Investors
Ranked
142nd among 214 active competitors
Employee Count
5 as on Jul 31, 2026
Similar Companies
Sign up to download CellType's company profile
CellType's funding and investors
CellType has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on Jan 01, 2026 for $*****. 1 investor participated in its latest round. CellType has 2 institutional investors.
Here is the list of recent funding rounds of CellType:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 01, 2026 | 1363476 | Seed | 9116069 | 1949794 | 4251468 | 9383162 |
Access funding benchmarks and valuations. Sign up today!View details of CellType's funding rounds and investors
CellType's founders and board of directors
Founder? Claim ProfileHere are the details of CellType's key team members:
- Ivan V: Co-Founder of CellType.
- David Van Dijk: Co-Founder & CEO of CellType.
View details of CellType's Founder profiles and Board Members
CellType's employee count trend
CellType has 5 employees as of Jul 26. Here is CellType's employee count trend over the years:
Uncover CellType's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CellType's Competitors and alternates
Top competitors of CellType include Schrodinger, Recursion Pharmaceuticals and Valo Health. Here is the list of Top 10 competitors of CellType, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 74/100 | |
2nd | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 72/100 | |
3rd |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 67/100 | |
4th |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
5th |  Isomorphic Labs 2021, London (United Kingdom), Series B | Digital platform focused on revolutionizing drug discovery using AI | $2.7B | 64/100 | |
6th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
7th |  In Silico 2014, Cambridge (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
8th |  Tandem AI 2021, New York (United States), Series A | AI-based drug discovery tool for researchers | $82M | 62/100 | |
9th | Causaly 2018, London (United Kingdom), Series B | Provider of an AI platform for life sciences and biomedical research | $93M | 62/100 | |
10th | Provider of an AI and quantum physics to discover therapeutic molecules | $101M | 62/100 | ||
142nd | CellType 2025, New York City (United States), Seed | AI-driven platform focused on drug discovery through biological simulation | $500K | 27/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on CellType's competitors? Click here to see the top ones
CellType's Investments and acquisitions
CellType has made no investments or acquisitions yet.
Reports related to CellType
Here is the latest report on CellType's sector:
News related to CellType
Media has covered CellType for 1 event in last 1 year, It was about partnerships.
•
Senhwa Biosciences & CellType Partner to Advance CX-4945 via AIPR Newswire•Mar 03, 2026•CellType, Senhwa Biosciences
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about CellType
Explore our recently published companies
- Drzavna lutrija Srbije - Serbia based, 2004 founded, Unfunded company
- Icepol Racing Team - Belgium based, 1992 founded, Unfunded company
- Lewis Wealth - Champaign based, Unfunded company
- Sankalpashree Wealth - Ujjain based, 2008 founded, Unfunded company
- Global Investment - Unfunded company
- Valley Fin - Canada based, Unfunded company
